SkinBioTherapeutics PLC Holding(s) in Company
2024年10月17日 - 3:00PM
RNS Regulatory News
RNS Number : 4806I
SkinBioTherapeutics PLC
17 October 2024
TR-1:
Standard form for notification of major holdings
2.
Reason for Notification
An acquisition or disposal of voting
rights
3.
Details of person subject to the notification
obligation
City
of registered office (if applicable)
Country of registered office (if applicable)
4.
Details of the shareholder
Full
name of shareholder(s) if different from the person(s) subject to
the notification obligation, above
City
of registered office (if applicable)
Country of registered office (if applicable)
5.
Date on which the threshold was crossed or
reached
6.
Date on which Issuer notified
7.
Total positions of person(s) subject to the notification
obligation
|
|
% of
voting rights attached to shares (total of 8.A)
|
% of
voting rights through financial instruments (total of 8.B 1 + 8.B
2)
|
Total of both in % (8.A + 8.B)
|
Total number of voting rights held in issuer
|
|
Resulting situation on the date on
which threshold was crossed or reached
|
4.100000
|
0.000000
|
4.100000
|
9347929
|
|
Position of previous notification
(if applicable)
|
3.100000
|
0.000000
|
3.100000
|
|
8.
Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A.
Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of
direct voting rights (DTR5.1)
|
% of
indirect voting rights (DTR5.2.1)
|
|
GB00BF33H870
|
9347929
|
|
4.100000
|
|
|
Sub Total 8.A
|
9347929
|
4.100000%
|
8B1. Financial Instruments according to (DTR5.3.1R.(1)
(a))
|
Type
of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument
is exercised/converted
|
% of
voting rights
|
|
|
|
|
|
|
|
Sub Total 8.B1
|
|
|
|
8B2. Financial Instruments with similar economic effect
according to (DTR5.3.1R.(1) (b))
|
Type
of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of
voting rights
|
|
|
|
|
|
|
|
|
Sub Total 8.B2
|
|
|
|
9.
Information in relation to the person subject to the notification
obligation
1. Person subject to the notification
obligation is not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding directly or
indirectly an interest in the (underlying) issuer.
|
Ultimate controlling person
|
Name
of controlled undertaking
|
% of
voting rights if it equals or is higher than the notifiable
threshold
|
% of
voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
|
|
|
|
|
10.
In case of proxy voting
The
number and % of voting rights held
The
date until which the voting rights will be held
11.
Additional Information
The previous submission included
warrants. We have now been advised that they should have been
excluded from the submission as they relate to shares that are not
currently in issue.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
HOLMFBATMTBBBFI
Skinbiotherapeutics (LSE:SBTX)
過去 株価チャート
から 10 2024 まで 11 2024
Skinbiotherapeutics (LSE:SBTX)
過去 株価チャート
から 11 2023 まで 11 2024
